Carbapenemases: Definition, Types, Significance, and Associated Bacteria
Carbapenemases represent the most clinically significant and versatile family of $beta$-lactamase enzymes, whose emergence poses a critical global threat to public health. They are defined by their capacity to hydrolyze a broad spectrum of $beta$-lactam antibiotics, including penicillins, cephalosporins, monobactams, and most critically, the carbapenems. The term ‘carbapenemase’ has become entrenched because the inactivation of carbapenems—often considered the last-resort treatment for severe multidrug-resistant (MDR) bacterial infections—is their most worrying clinical consequence. These enzymes are key drivers of antimicrobial resistance (AMR), allowing bacteria to evade the most powerful available antibiotics, thereby compromising the treatment of serious hospital-acquired and community-acquired infections.
The genes encoding carbapenemases are frequently found on mobile genetic elements, such as plasmids and transposons. This plasmid-mediated transmission is the central factor behind their rapid and widespread dissemination across different species of bacteria and geographical regions. This horizontal gene transfer mechanism transforms what might have once been a problem of clonal spread into a global epidemic challenge.
Clinical and Public Health Significance of Carbapenemases
The significance of carbapenemase production is profound, as it directly compromises the effectiveness of carbapenem antibiotics like imipenem and meropenem. These drugs are essential for treating severe infections caused by Gram-negative bacteria, particularly in immunocompromised patients or those with infections resistant to first- and second-line agents. When bacteria produce carbapenemases, the resulting infections—such as bloodstream infections, pneumonia, and urinary tract infections—become extremely difficult, and in some cases, impossible to treat due to resistance to all but a handful of therapeutic options. This leads to a cascade of negative outcomes: increased morbidity and mortality rates, prolonged hospital stays, higher healthcare costs, and the desperate necessity to use older, more toxic antibiotics like colistin.
The World Health Organization (WHO) has recognized carbapenem-resistant Gram-negative bacteria, including carbapenemase-producing Enterobacterales (CPE), *Pseudomonas aeruginosa*, and *Acinetobacter baumannii*, as critical-priority pathogens, highlighting the urgent need for new antibiotics and effective infection control strategies. The global spread of these enzymes, particularly the most effective families, is an ongoing public health emergency that demands continuous surveillance and rapid, accurate laboratory detection for timely patient isolation and treatment modification.
Molecular Classification and Hydrolytic Mechanism
Carbapenemases are structurally classified according to the Ambler molecular classification system into three major classes: A, B, and D. This classification is crucial because it dictates the enzyme’s hydrolytic mechanism and, consequently, its susceptibility to $beta$-lactamase inhibitors.
Classes A and D carbapenemases are known as **Serine Carbapenemases**. They possess a serine residue at their active site, which is essential for hydrolyzing the $beta$-lactam ring. Enzymes in this group, such as the KPC (Class A) and OXA-48 (Class D) families, are often only partially inhibited by traditional $beta$-lactamase inhibitors like clavulanic acid and tazobactam, and sometimes require newer inhibitors, such as relebactam, to restore carbapenem activity.
Class B carbapenemases are fundamentally different and are referred to as **Metallo-$beta$-lactamases (MBLs)**. They require one or two zinc atoms at their active site to facilitate the hydrolysis of the $beta$-lactam ring. As metalloenzymes, MBLs are characteristically inhibited by metal chelators like EDTA (Ethylenediaminetetraacetic acid), but crucially, they are resistant to all commercially viable serine $beta$-lactamase inhibitors (clavulanic acid, tazobactam). A key diagnostic difference is that MBLs, such as the NDM, IMP, and VIM families, typically cannot hydrolyze the monobactam antibiotic aztreonam, while many Class A and D enzymes can.
Major Families and their Global Epidemiology
Among the multitude of carbapenemase variants, five families have achieved a dominant position in clinical isolates globally, collectively referred to as ‘The Big Five’: KPC, IMP, VIM, NDM, and OXA-type enzymes.
The **KPC (Klebsiella pneumoniae Carbapenemase)** family is the most prevalent Class A carbapenemase, first identified in the United States in *K. pneumoniae* but has since disseminated widely across the globe and in various Enterobacteriaceae. It is notorious for being plasmid-encoded and associated with the successful clonal complex ST258 in the US and ST11 in China, making it highly transmissible.
The most widespread Class B MBLs include **NDM (New Delhi Metallo-$beta$-lactamase)**, **IMP (Imipenemase)**, and **VIM (Verona Integron-encoded Metallo-$beta$-lactamase)**. NDM, discovered in 2008, has exhibited a spectacular and rapid global spread, primarily from the Indian subcontinent, and is a major concern in healthcare settings. IMP-1, one of the first MBLs detected in 1991, and VIM-1, found in 1997, have also successfully spread to all continents, often being associated with non-fermenting bacteria, especially *Pseudomonas aeruginosa*.
The **OXA-type enzymes** (e.g., OXA-48) constitute the most significant Class D carbapenemases. While some OXA variants (like OXA-23, -24, -58) are classic to *Acinetobacter baumannii*, OXA-48 and its variants are globally prevalent in Enterobacteriaceae, particularly *Klebsiella pneumoniae*. OXA-48 is often associated with a highly mobile and successful plasmid, further driving its rapid spread across different bacterial hosts.
Primary Carbapenemase-Producing Bacteria
While carbapenemases can theoretically be found in many bacteria, their clinical importance is overwhelmingly concentrated in three major groups of Gram-negative pathogens:
- Enterobacterales: This family includes key clinical species like *Klebsiella pneumoniae*, *Escherichia coli*, and *Enterobacter* spp. Carbapenemase-Producing Enterobacterales (CPE), which are often Carbapenem-Resistant Enterobacterales (CRE), are of critical concern because they are normal gut flora and can spread rapidly in hospital environments. KPC, NDM, and OXA-48 are the most common carbapenemases in this group.
- *Pseudomonas aeruginosa*: A prominent non-fermenting bacterium often associated with nosocomial infections. *P. aeruginosa* frequently harbors MBLs such as VIM and IMP-type carbapenemases, which are difficult to treat.
- *Acinetobacter baumannii* Complex: Another non-fermenter notorious for causing infections in intensive care units. Carbapenem resistance in this species is frequently mediated by OXA-type carbapenemases, such as OXA-23, OXA-24, and OXA-58.
The confluence of carbapenemase production and the mobility of the resistance genes in these prevalent and opportunistic pathogens has created a challenging clinical environment, underscoring the necessity for robust antimicrobial stewardship, diligent infection control measures, and continued research into novel therapeutic agents.